ORIC Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 17 analysts polled by S&P Global, ORIC Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $20.29. The average 1-year stock price forecast is 138.99% higher than the current stock price, while the lowest is $14 (+64.90%) and the highest is $25 (+194.46%).

Price Target: $20.29 (+138.99%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$14	$20.29	$21	$25
Change	+64.90%	+138.99%	+147.35%	+194.46%

Analyst Ratings

The average analyst rating for ORIC Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	12	12	12	12	13	14
Buy	2	2	2	2	2	2
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	15	15	15	15	16	17

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Laura Prendergast Stifel Nicolaus	Stifel Nicolaus	Buy Initiates $14	Buy	Initiates	$14	+64.90%	Jun 11, 2026
Derek Archila Wells Fargo	Wells Fargo	Buy Reiterates $25	Buy	Reiterates	$25	+194.46%	Jun 11, 2026
Robert Burns H.C. Wainwright	H.C. Wainwright	Buy Reiterates $25	Buy	Reiterates	$25	+194.46%	Jun 8, 2026
Corinne Johnson Goldman Sachs	Goldman Sachs	Buy Reiterates $15	Buy	Reiterates	$15	+76.68%	Jun 3, 2026
Unknown Analyst Wedbush No rating	Wedbush	Buy Initiates $17	Buy	Initiates	$17	+100.24%	May 5, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-1.46

from -1.47

EPS Next Year

-1.57

from -1.46

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	-	-	-
Operating Income	-78.87M	-86.77M	-110.78M	-142.90M	-143.00M	-168.44M
Net Income	-78.72M	-89.12M	-100.70M	-127.85M	-129.47M	-155.48M
EPS	-	-	-	-	-1.47	-1.46
Free Cash Flow	-32.71M	-42.02M	-49.08M	-67.10M	-69.10M	-107.00M
No. Analysts	-	-	-	-	-	13

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Revenue Growth	2027	2028
High	-
Avg	-
Low	-

EPS Forecast

EPS	2026	2027	2028
High	-1.30
Avg	-1.46
Low	-1.66

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-